FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Guidance on Advisory Panel Members Financial Information

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance on public availability of advisory committee members financial interest inf...

Most Effective DTC Messages Deal with Symptoms

[ Price : $8.95]

MedTrackAlert says consumers respond best to ads that are relevant and deal with disease symptoms.

FDA OKs Allergans Combigan for Glaucoma

[ Price : $8.95]

FDA approves an Allergan NDA for Combigan, indicated for reducing elevated intraocular pressure in patients with glaucoma or ocula...

BioDelivery Sciences Submits Fentanyl NDA

[ Price : $8.95]

BioDelivery Sciences International submits an NDA for Bema (fentanyl), indicated for treating breakthrough cancer pain.

Satraplatin Fails Pivotal Trial

[ Price : $8.95]

GPC Biotechs satraplatin fails to meet the overall survivability endpoint of its Phase 3 hormone-refractory prostate cancer pivota...

Guidance on HIV Resistance Testing

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance on the role of HIV resistance testing in antiretroviral drug development.

FDA Guide on HIV Resistance Testing

[ Price : $8.95]

FDA says it wants more HIV resistance testing during antiretroviral drug development and post-marketing periods.

State Law Stops Access to Health Info: WLF

[ Price : $8.95]

Washington Legal Foundation calls on a federal appeals court to uphold a lower court ruling against a New Hampshire law banning co...

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites CoLigne, GE Infrastructure, Heartland Products, and Sanofi-Aventis.

sNDA Submitted for Aloxi Oral Formulation

[ Price : $8.95]

MGI Pharma and Helsinn Healthcare submit a supplemental NDA for an oral capsule formulation of injectable nausea drug Aloxi.